科伦药业
(002422)
| 流通市值：422.85亿 | | | 总市值：517.45亿 |
| 流通股本：13.06亿 | | | 总股本：15.98亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 13,276,729,763 | 9,083,327,620 | 4,389,897,045 | 21,812,414,489 |
| 营业收入 | 13,276,729,763 | 9,083,327,620 | 4,389,897,045 | 21,812,414,489 |
| 二、营业总成本 | 11,864,487,373 | 7,818,465,981 | 3,728,008,892 | 17,850,873,646 |
| 营业成本 | 6,918,962,787 | 4,563,768,076 | 2,253,369,848 | 10,536,820,557 |
| 税金及附加 | 187,048,638 | 121,486,067 | 53,276,967 | 276,224,683 |
| 销售费用 | 2,149,031,228 | 1,436,968,307 | 631,306,696 | 3,492,619,258 |
| 管理费用 | 930,472,675 | 616,388,260 | 301,812,127 | 1,308,491,117 |
| 研发费用 | 1,632,571,034 | 1,048,156,976 | 484,116,428 | 2,170,538,644 |
| 财务费用 | 46,401,011 | 31,698,295 | 4,126,826 | 66,179,387 |
| 其中:利息费用 | 83,743,427 | 53,757,701 | 26,524,013 | 151,624,891 |
| 其中:利息收入 | 50,582,017 | 22,871,210 | 12,674,548 | 71,603,649 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 21,419,033 | 15,139,177 | 7,630,072 | 19,898,352 |
| 加:投资收益 | 177,596,768 | 133,059,225 | 61,314,415 | 345,018,134 |
| 资产处置收益 | 5,742,400 | 6,486,961 | 597,484 | 807,537 |
| 资产减值损失(新) | -66,882,298 | -66,882,298 | - | -130,590,378 |
| 信用减值损失(新) | -36,107,467 | -28,311,025 | -6,412,142 | -109,130,422 |
| 其他收益 | 265,898,241 | 189,083,515 | 68,719,707 | 338,777,395 |
| 四、营业利润 | 1,779,909,067 | 1,513,437,194 | 793,737,689 | 4,426,321,461 |
| 加:营业外收入 | 4,640,487 | 2,471,001 | 1,070,451 | 8,810,007 |
| 减:营业外支出 | 135,619,472 | 98,258,746 | 21,623,438 | 149,772,644 |
| 五、利润总额 | 1,648,930,082 | 1,417,649,449 | 773,184,702 | 4,285,358,824 |
| 减:所得税费用 | 404,159,564 | 303,793,046 | 113,597,226 | 923,404,431 |
| 六、净利润 | 1,244,770,518 | 1,113,856,403 | 659,587,476 | 3,361,954,393 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,244,770,518 | 1,113,856,403 | 659,587,476 | 3,361,954,393 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,200,665,720 | 1,000,625,359 | 584,242,512 | 2,935,892,103 |
| 少数股东损益 | 44,104,798 | 113,231,044 | 75,344,964 | 426,062,290 |
| 扣除非经常损益后的净利润 | 1,146,949,563 | 985,477,298 | 564,434,551 | 2,902,354,246 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.75 | 0.63 | 0.37 | 1.86 |
| (二)稀释每股收益 | 0.75 | 0.63 | 0.37 | 1.86 |
| 八、其他综合收益 | -43,268,342 | -39,588,443 | -6,264,066 | 11,139,131 |
| 归属于母公司股东的其他综合收益 | -38,592,854 | -38,629,367 | -7,809,259 | 14,170,642 |
| 九、综合收益总额 | 1,201,502,176 | 1,074,267,960 | 653,323,410 | 3,373,093,524 |
| 归属于母公司股东的综合收益总额 | 1,162,072,866 | 961,995,992 | 576,433,253 | 2,950,062,745 |
| 归属于少数股东的综合收益总额 | 39,429,310 | 112,271,968 | 76,890,157 | 423,030,779 |
| 公告日期 | 2025-10-31 | 2025-08-29 | 2025-04-30 | 2025-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |